Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs MB-103 (Primary) ; MB-103 (Primary)
- Indications Glioma
- Focus Adverse reactions
- 19 Jun 2019 Planned number of patients changed from 36 to 42.
- 19 Jun 2019 Planned End Date changed from 1 Aug 2021 to 14 Jun 2021.
- 19 Jun 2019 Planned primary completion date changed from 1 Aug 2021 to 14 Jun 2021.